Drugs / JC-013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06169059 | Oct → Nov 2023 | — | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JC-013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06169059 ↗ |
| Action | Inhibit | “COX-2 inhibitor” NCT06169059 ↗ |